ANVS News and Press, Annovis Bio Inc.

Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections Study completion on track: symptomatic data readout - Q1 2027, disease-modifying data readout - Q1 2028 Company positions for two NDA submissions following each readout MALVERN, Pa., July 07, 2026 (GLOBE NEWSWIR...

2026-07-01 09:35:22 ET Annovis Bio (NYSE: ANVS) announced the promotion of Cheng Fang, Ph.D., to chief scientific officer. Fang, who joined the company in 2021 and most recently served as senior vice president of research and development, will oversee scientific strategy and research op...

MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’...

2026-05-26 09:55:00 ET Annovis Bio (NYSE: ANVS) , a Phase 3 clinical-stage biotechnology company developing buntanetap for Alzheimer’s disease and Parkinson’s disease, announced it has regained compliance with New York Stock Exchange continued listing standards after imple...

2026-05-26 08:22:10 ET More on Annovis Bio Annovis Bio slips after pricing $15M equity offering Seeking Alpha’s Quant Rating on Annovis Bio Historical earnings data for Annovis Bio Financial information for Annovis Bio Read the full article o...

MALVERN, Pa., May 26, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s...

2026-05-20 09:40:52 ET More on Annovis Bio Seeking Alpha’s Quant Rating on Annovis Bio Historical earnings data for Annovis Bio Financial information for Annovis Bio Read the full article on Seeking Alpha For further details see: Annovis Bi...

2026-05-20 09:38:07 ET Annovis Bio (NYSE: ANVS) announced the pricing of an underwritten public offering of 7,895,000 shares of common stock and accompanying warrants to purchase up to 7,105,500 additional shares at a combined offering price of $1.90 per share a...

MALVERN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's diseas...

2026-05-19 16:29:53 ET More on Annovis Bio Seeking Alpha’s Quant Rating on Annovis Bio Historical earnings data for Annovis Bio Financial information for Annovis Bio Read the full article on Seeking Alpha For further details see: Annovis la...